Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corrective Actions "Inadequate," FDA Warns Ranbaxy

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. regulators threaten seizure and injunction at Ohm Labs' Gloversville, N.Y., facility.

You may also be interested in...



The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

Lipitor Patent Battle: Pfizer Plots New Course In Suit With Apotex

Two years ago, Pfizer inked a settlement with Ranbaxy, the first ANDA filer for generic Lipitor, that it believed would prevent generic competition in the U.S. until November 2011

Related Content

Topics

UsernamePublicRestriction

Register

PS070301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel